Trial Profile
Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs ADhVN120304.H5 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions; Proof of concept
- Sponsors Altimmune
- 11 Apr 2019 According to an Altimmune media release, data from this study will be presented at the World Vaccine Congress being held in Washington D.C. on April 14-17, 2019. The presentation will take place on April 16, 2019 at the Renaissance Washington, DC Downtown Hotel.
- 11 Apr 2019 Results published in the Altimmune Media Release
- 28 Nov 2018 Status changed from active, no longer recruiting to completed.